Can you take Botox with Levothyroxine?

Levothyroxine has a major potential interaction with Adrenal Insufficiency.

The use of thyroid hormones is contraindicated in patients with uncorrected adrenal insufficiency. Thyroid hormones increase tissue demand for adrenocortical hormones and may precipitate acute adrenal crisis. In patients with controlled adrenal insufficiency or other endocrine disorders, therapy for these concomitant disorders may need to be adjusted following thyroid replacement, since hypothyroidism often obscure or diminish the signs and symptoms of these conditions. Clinical monitoring of thyroid and adrenal function as well as any other appropriate endocrine function is recommended during thyroid hormone therapy.

Levothyroxine has a moderate potential interaction with Diabetes Insipidus.

Since hypothyroidism often obscure or diminish the signs and symptoms of endocrine disorders such as diabetes mellitus or diabetes insipidus, thyroid replacement therapy may aggravate the intensity of symptoms associated with these conditions. Patients with endocrine disorders should be monitored more closely during thyroid hormone therapy, and their medication regimen adjusted accordingly. If thyroid medication is later discontinued, a downward readjustment of insulin or oral hypoglycemic agent may be necessary in patients with diabetes mellitus to avoid hypoglycemia.

Levothyroxine has a moderate potential interaction with Diabetes Mellitus.

Since hypothyroidism often obscure or diminish the signs and symptoms of endocrine disorders such as diabetes mellitus or diabetes insipidus, thyroid replacement therapy may aggravate the intensity of symptoms associated with these conditions. Patients with endocrine disorders should be monitored more closely during thyroid hormone therapy, and their medication regimen adjusted accordingly. If thyroid medication is later discontinued, a downward readjustment of insulin or oral hypoglycemic agent may be necessary in patients with diabetes mellitus to avoid hypoglycemia.

The onabotulinumtoxinA in Botox has a major potential interaction with Dysphagia.

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.

Levothyroxine has a major potential interaction with Heart Disease.

Thyroid hormones cause increases in myocardial contractility and heart rate as a result of increased metabolic demands and oxygen consumption. Therapy with thyroid hormones should be administered cautiously and initiated at reduced dosages in patients with cardiovascular disorders such as angina, coronary artery disease, and hypertension. Clinical monitoring of cardiovascular function is recommended. If chest pain or exacerbation of cardiovascular disease occurs, the dosage of thyroid hormone should be reduced, even at the expense of achieving euthyroid state. Thyroid hormones should not be administered to patients with an acute myocardial infarction that is not complicated by hypothyroidism.

Levothyroxine has a major potential interaction with High Blood Pressure.

Thyroid hormones cause increases in myocardial contractility and heart rate as a result of increased metabolic demands and oxygen consumption. Therapy with thyroid hormones should be administered cautiously and initiated at reduced dosages in patients with cardiovascular disorders such as angina, coronary artery disease, and hypertension. Clinical monitoring of cardiovascular function is recommended. If chest pain or exacerbation of cardiovascular disease occurs, the dosage of thyroid hormone should be reduced, even at the expense of achieving euthyroid state. Thyroid hormones should not be administered to patients with an acute myocardial infarction that is not complicated by hypothyroidism.

Levothyroxine has a major potential interaction with Hyperthyroidism.

The use of thyroid hormones is contraindicated in patients with untreated thyrotoxicosis of any etiology, since thyroid hormones may exacerbate the condition.

The onabotulinumtoxinA in Botox has a major potential interaction with Infection.

Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, letibotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).

The onabotulinumtoxinA in Botox has a major potential interaction with Myasthenia Gravis.

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.

The onabotulinumtoxinA in Botox has a major potential interaction with Pulmonary Impairment.

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.

Levothyroxine has a moderate potential interaction with Seizures.

Thyroid hormones may alter the seizure threshold. Seizures have been reported rarely following the initiation of levothyroxine therapy. Therapy with thyroid hormones should be administered cautiously in patients predisposed to seizures.

The onabotulinumtoxinA in Botox has a major potential interaction with Urinary Retention.

Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.

The onabotulinumtoxinA in Botox has a major potential interaction with Urinary Tract Infection.

Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.